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resulting in return of platelets to the resting state (Mar-
cus et al., 1997; Kaczmarek et al., 1996). This action
of CD39 is thought to modulate intravascular platelet
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accumulation and help localize thrombus formation toWeill Medical College of Cornell University
the setting of tissue injury (Marcus and Safier, 1993).New York, New York 10021
Thus, limitation and control of platelet reactivity by CD392 Department of Cardiovascular and
is a critical component of hemostasis and thrombotic re-Metabolic Diseases
actions.Wyeth Research
Interestingly, hematophagous arthropods have evolved200 Cambridge Park Drive
the ability to inhibit the ADP-induced activation of hostCambridge, Massachusetts 02140
platelets, thus facilitating blood feeding, by secreting
apyrases (EC 3.6.1.5) from their salivary glands (Basa-
nova et al., 2002). These enzymes hydrolyze ADP intoSummary
AMP in the presence of Ca2, and thus exert an anti-
thrombotic effect by removal of this potent inducer ofHematophagous arthropods secrete a salivary apyr-
platelet aggregation. Insect apyrases are members of aase that inhibits platelet activation by catabolizing ADP
family of extracellular nucleotidases that require Ca2released from damaged tissues and blood cells. We
for their activity and are insensitive to specific inhibitorsreport the X-ray crystal structures of a human enzyme
of P-, F-, and V-type ATPases (Smith et al., 2002; Failerof the soluble apyrase family in its apo state and bound
et al., 2002). No consensus sequences for known nucle-to a substrate analog. The structures reveal a nucleo-
otide binding domains have been found for this familytide binding domain comprising a five-blade  propel-
of enzymes, and there is consequently no structuraller, binding determinants of the substrate and the ac-
precedent for defining their substrate characteristics.tive site, and an unusual calcium binding site with
Sequence alignment reveals that these insect enzymesa potential regulatory function. Using a comparative
are closely related to a second subfamily of proteinsstructural biology approach, we were able to redesign
including human apyrase that is characterized by athe human apyrase so as to enhance its ADPase activ-
highly conserved N-terminal sequence and 75%ity by more than 100-fold. The engineered enzyme is
amino acid overall identity among known vertebrate ho-a potent inhibitor of platelet aggregation and may
mologs (Smith et al., 2002). In striking contrast to insectserve as the basis for the development of a new class
subfamily members, human and rat apyrases have beenof antithrombotic agents.
shown to prefer GDP and UDP as substrates (Smith
et al., 2002; Failer et al., 2002). If the catalytic activityIntroduction
observed in vitro reflects the ability of these enzymes
to hydrolyze their in vivo substrates, it seems likely thatElevated levels of ATP and ADP can arise as a conse-
distinct members within the apyrase family may share aquence of vascular injury in coronary, cerebral, and pe-
common catalytic mechanism while exhibiting differentripheral arteries. Both compounds have been implicated
substrate specificity. Rat apyrase has been shown toas purinergic signaling molecules in a variety of inflam-
reside in the endoplasmic reticulum, and it has beenmatory processes with effects on platelets, endothelial
proposed that it plays an intracellular role in glycosyla-cells, and leukocytes (Luthje, 1989). ADP is a major
tion reactions (Failer et al., 2002). A detailed mechanistic
platelet recruiting factor originating from the dense gran-
understanding of catalysis and substrate specificity in
ules of human platelets. Circulating platelets are usually
the apyrase family has been hindered by the lack of
kept in an inactive state by prostacyclin and nitric acid three-dimensional structural information.
(NO) released by the endothelial cells. Upon vascular Development of therapeutic agents for inhibition of
damage, the platelets adhere to exposed collagen in platelet function more effectively and safely is the sub-
the subendothelium, become activated, and secrete ject of intense pharmaceutical efforts. Metabolic re-
ADP and several other biologically active ligands includ- moval of ADP released from the stimulated platelets
ing thromboxane A2 and serotonin. Micromolar concen- without infliction of platelet damage represents an at-
trations of ADP are sufficient to cause platelets to tractive approach in this endeavor. Indeed, soluble re-
change shape from a smooth discoid shape to spicu- combinant CD39 has been shown to be a beneficial
lated spheres, leading to platelet deposition at the site therapeutic in animal models of experimental stroke and
of injured vasculature. ADP thus acts as a powerful para- provides a potential treatment option in ischemic injury
crine signal for the efficient recruitment of circulating (Pinsky et al., 2002). It should be emphasized that the
platelets to the developing thrombus. ADP-induced human apyrase described here shares no sequence ho-
platelet activation is primarily counteracted by CD39/ mology with CD39. In addition, the two enzymes differ
ecto-apyrase on the endothelial cell surface which rap- in both substrate specificity and cation preference
idly metabolizes ADP released from activated platelets, (Smith et al., 2002). In this report, we present the high-
resolution crystal structures of apo and substrate analog
bound states of human apyrase, revealing the nucleotide*Correspondence: mlu@med.cornell.edu
3 These authors contributed equally to this work. binding motif and outlining a Ca2-dependent catalytic
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Table 1. Summary of Crystallographic Analysis
Diffraction Data
Data Set Native SeMet 1 SeMet 2 SeMet 3 GMP-CP
Wavelength (A˚) 0.9795 0.9790 0.9794 0.9687 0.9795
Resolution (A˚) 72.6–1.7 50–1.7 50–1.7 50–1.75 46.6–1.6
Rsyma (%) 5.7 (23.8)b 5.5 (39.5) 5.6 (39.8) 6.3 (38.1) 5.9 (34.8)
Completeness 95.3 (79.2) 95.0 (94.7) 96.1 (94.9) 96.2 (95.3) 95.0 (93.8)
I/(I) 14.3 (3.5) 12.1 (2.5) 12.3 (2.5) 10.8 (2.6) 12.0 (2.3)
Phasing
Resolution (A˚) 20–2.7
No. of sites 10
Phasing power (ano/iso)c 0.6/0.7 0.5/1.1 0.5/–
Overall figure of meritd 0.55
Refinement
Resolution range (A˚) 72.6–1.7 46.6–1.6
No. of reflections 62,309 79,084
Total No. of atoms 5598 5776
Rcryst/Rfreee (%) 15.7/19.1 16.4/19.4
Rmsd bond lengths (A˚) 0.016 0.015
Rmsd bond angles (deg.) 1.5 1.5
Average B factor (A˚2) 19.0 18.4
Rmsd B values (A˚2) 1.9 1.7
a Rsym  |I  I|/I, where I is the integrated intensity of a given reflection.
b Numbers in parentheses represent the statistics for the shell comprising the outer 10% (theoretical) of the data.
c Phasing power  |FH|/||FPH (obs)|  |FPH (calc)||, where FH is the calculated heavy atom structure factor amplitude.
d Overall figure of merit  |(	)ei	/|P(	)|, where 	 is the phase and P(	) is the phase probability distribution.
e Rcryst  |F(obs)  F(calc)|/F(obs), Rfree  Rcryst calculated using 5% random data omitted from the refinement.
mechanism for the apyrase family. Furthermore, we em- contains two protein monomers (residues 19–333), each
bound to GMP-CP and a Ca2 ion.ploy a structure-based approach to redesign a human
apyrase variant capable of selectively and efficiently
hydrolyzing ADP. The engineered enzyme is a potent
inhibitor of human platelet reactivity, thus demonstra- Structure of Apo Human Apyrase
The apo structure reveals an unusual five-bladed 
 pro-ting the potential utility of this agent to improve current
antiplatelet therapy. peller (residues 34–333) preceded by a 15 amino acid
N-terminal subdomain (residues 19–33) that is joined to
the propeller by 
 sheet interactions (Figures 1A andResults and Discussion
1B). The five twisted 
 sheets (1–5), each formed from
four antiparallel 
 strands (a, b, c, and d), are radiallyExpression and Structure Determination
We crystallized human apyrase (residues 3–333) and its arranged around a central tunnel. The interface between
neighboring blades is predominantly hydrophobic, withcomplex with the nucleotide guanosine 	/
-methylene
diphosphate (GMP-CP). GMP-CP was chosen as a sub- residues on the adjacent faces of the 
 sheets in van
der Waals contact. The central tunnel is slightly conicalstrate analog because human apyrase prefers a guano-
sine or uridine base in the substrate with cleavage al- in shape and is lined with amide and carbonyl oxygen
groups from the edges of the five inner (a) strands, withways resulting in the release of a monophosphate
nucleotide (Smith et al., 2002). The recombinant protein only a few side chains projecting into the cavity. The
propeller has an approximate diameter of 44 A˚ andwas expressed in E. coli and refolded as a soluble, active
enzyme by renaturation from urea. Analytical ultracen- height of 30 A˚. The polypeptide chain enters the propel-
ler as strand 1b, follows the 
 sheet topology by buildingtrifugation measurements indicate that the enzyme ex-
ists as a monomer in solution. The structure of the apo up a sheet from the inside to the outside, continues
through each blade in turn, and ultimately exits the pro-enzyme was determined at 1.7 A˚ resolution by the
method of multiwavelength anomalous diffraction (Hen- peller at the C terminus of strand 1a. Thus, the backbone
enters and leaves the propeller at adjacent positions ondrickson, 1991) using a selenomethionine derivative. It-
erative model building and crystallographic refinement the “bottom face” of the molecule (the “top face” is the
opposite surface), and the 
 interaction of strands 1aresulted in a model with an R factor of 15.7% and a free
R value of 19.1% (Table 1). The final model of the apo and 1b appears to tighten the circular belt of the ring
structure (Murzin, 1992). Interestingly, the N terminus ofstructure contains two apoprotein molecules (residues
19–333) and two Ca2 ions. The crystal structure of the the molecule wraps around and contributes two addi-
tional antiparallel strands (
I and 
II) to the first blade,substrate analog complex was solved at 1.6 A˚ resolution
by molecular replacement using the apo structure as a making it six-stranded (Figure 1B). This N-terminal ex-
tension, based on a comparative analysis of the packingsearch model. The model of the complex has an R factor
of 16.4% and a free R value of 19.4% (Table 1). It, too, of sheets in 
 propeller structures (Fulop and Jones,
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Figure 1. Structure of Apo Human Apyrase
Ribbon diagram of the human apyrase pro-
peller structure as viewed along (A) or per-
pendicular to (B) the central tunnel. The
sheets are numbered 1 to 5 and organized
sequentially in a counterclockwise direction,
and the four antiparallel 
 strands within each
sheet are denoted a to d in the order from axis
to perimeter. The 
 propeller is circularized by
juxtaposition of the 1a and 1b strands. The
polypeptide chain is colored from blue at the
N terminus through to red at the C terminus.
The Ca2 ion (green sphere) is located in the
middle of the central tunnel.
(C) Superposition of the 	 carbon traces of the
five blades of the human apyrase propeller.
Blades 2 and 5 (green and light blue) have
the shortest loops between 
 strands. Blades
1, 3, and 4 (gray, yellow, and pink) have at
least one long loop projecting from the top
face of the 
 propeller.
(D) Stereoview of the 2Fo Fc electron density
map (contoured at 1.5) showing the coordi-
nation geometry of the Ca2 ion (green sphere)
connecting the five blades of the human apyr-
ase propeller. Water molecules are shown as
red spheres, and calcium coordinations are
denoted by dotted lines.
(E) Sequence alignment of the five blades of
the human apyrase propeller. The approxi-
mate boundaries of the 
 strands are high-
lighted. φ designates conserved hydropho-
bic residues.
1999), may well contribute to the structural stability of apyrase propeller is quite variable because of significant
differences in the interstrand loops. The location andthe uncommon five-bladed propeller fold.
Human and insect apyrases have not been previously lengths of these loop insertions distinguish human apyr-
ase from other 
 propeller proteins. In contrast to mostrecognized as 
 propeller proteins because they lack
detectable internal sequence repeats. Thus, sequence known 
 propellers that have approximately 40–45 resi-
dues per blade, the human apyrase blades average 66signatures associated with 
 propellers, such as the
WD40 (Wall et al., 1995) or RCC1 (Renault et al., 1998) amino acids in length (Figure 2). As a result, human
apyrase has some noteworthy surface features. Thererepeats, are not found in apyrase proteins. Apparently,
there are alternative solutions to the topological problem are protrusions from the top and bottom faces of the
propeller that emanate as noncanonical loops fromof folding a 
 propeller. In spite of the absence of typical

 propeller repeats, the close sequence similarity of blades 1, 3, 4, and 5. The largest loop insertion between
blades 3 and 4 contains an additional helix (	I) and aapyrases from species as distantly related as insect and
human allows the three-dimensional structure pre- strand (
III). Importantly, the loops that project from the
top face are held in place through extensive contactssented here to serve as a useful model for the apyrase
family in general. The individual blades of the human both with each other and with the modular sheets so
as to form a novel nucleotide binding motif (see below).apyrase propeller can be superimposed on each other
with rmsd for	carbon atoms of 1.8–2.1 A˚ and with better
superposition of inner than of outer strands (Figure 1C). Calcium Binding Site
During refinement of the apo structure, a strong spheri-However, even a structure-based alignment of the amino
acid sequence of each human apyrase propeller blade cal peak of electron density appeared on the central
axis of the propeller near Ser100, which could not be(Figure 1E) reveals no striking repetitive features, al-
though a structurally conserved clustering of hydropho- adequately accounted for by a water molecule (Figure
1D). Modeling this peak as a strontium ion (present in thebic residues at positions of contact between successive
sheets is clearly evident. This observation supports the crystallization buffer) resulted in an anomalously high
individual B-factor value of 21.5 A˚2 as compared withview that the driving force for 
 propeller formation is
the hydrophobic packing at the intersheet cores (Fulop an average value of 12.4 A˚2 for the six coordinating
oxygen atoms surrounding the site. In contrast, theand Jones, 1999).
The number of residues in each blade of the human B-factor refinement of the modeled calcium ion con-
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Figure 2. Structure-Based Alignment of Human Apyrase with Other Apyrase Proteins
The sequence of human apyrase (residues Pro1–Ile333) is shown with the elements of secondary structure indicated above the alignment.
Gray arrows and cylinders mark 
 strands and 	 helices, respectively, with crosses denoting residues that are disordered in the present apo
and substrate analog structures. The sequences of human, rat, bed bug, and sand fly (Phlebotomus) are shown; in these cases the enzymatic
activity has been established by biochemical analysis. Residues that are important for nucleotide and Ca2 binding are indicated by pluses
and asterisks, respectively. Chemically similar residues in the apyrase family are colored red and residues conserved in the vertebrate and
insect subfamilies in blue and green, respectively. We refer to the human apyrase structure using the numbering system of the mature protein.
verges at 8.3 A˚2. The identity of the divalent cation was tion on the thermostability of human apyrase. Indeed,
we find a marked decrease in the midpoint (tm value) ofconfirmed by the observation of a peak at the calcium
K edge (4038.5 eV) by X-ray absorption spectroscopy. the thermal unfolding transition, from 64C to 57C, upon
removal of calcium ion by EDTA chelation (data notThus, we have identified a Ca2 binding site in the middle
of the central tunnel. Calcium is coordinated by the shown). This result, in conjunction with the structural
data, clearly implicates calcium binding in stabilizingcarbonyl oxygen atoms of Ser100 (from strand 
2a),
Glu147 (from 2d–3a loop), Glu216 (from 3d–4a loop), human apyrase.
Ser277 (from strand 
5a), and Glu328 (from strand 
1a)
in the roughly elliptical cross-section of the propeller at The Nucleotide Binding Site and Catalytic Center
The structure of human apyrase in the presence of thedistances ranging from 2.43 A˚ to 2.87 A˚ (Figure 1D), thus
linking together five blades that are remote from one substrate analog GMP-CP at 1.6 A˚ shows that the nucle-
otide binding site is located on the top face of the propel-another in the primary sequence of the enzyme. In addi-
tion, the Ca2 ion contacts a water molecule and the ler and is largely exposed to solvent, allowing nucleotide
to enter and exit the binding site without steric obstruc-carboxylate group of Asp101 in strand 
2a from the top
and bottom faces of the propeller, respectively. The tion (Figure 3A). The GMP-CP ligand, tucked into a deep
pocket toward one end of the central tunnel, was de-two monomers in the asymmetric unit adopt the same
pentagonal bipyramid calcium coordination geometry tected in a Fo  Fc difference map (Figure 3C). This
pocket is framed by loop insertions IV–VII and flanked(rmsd between equivalent C	 positions of 0.13 A˚). With
the exception of a conservative glutamate substitution by the side chains of Asp46, Lys233, and Glu297. The
guanine ring of GMP-CP is caged by the concentricallyfor Asp101, the calcium binding residues are invariant
in all apyrase proteins (Figure 2). stacked rings of Trp165 and Tyr239 (buttressed by
Gly160, Leu161, Lys163, and Ile214) (Figure 3D). ThisThe role of calcium binding in tethering the five blades
of the human apyrase propeller suggests that Ca2 may highly conserved cleft ensures a snug fit for the guanine
base and provides the majority of contact surface be-help to rigidify the central tunnel surrounded by connect-
ing loops. If so, one would anticipate that depletion of tween the enzyme active site and the bound nucleotide.
In addition, the side chain of Tyr239 is oriented so ascalcium ion would decrease the stability of the cyclic
structure. To address this issue, circular dichroism ex- to allow its hydroxyl group to make bifurcated hydrogen
bonds with the guanine ring and ribose of the ligandperiments were used to assess the effects of Ca2deple-
Protein Design of a Platelet Function Inhibitor
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Figure 3. Structure of Human Apyrase in Complex with GMP-CP Substrate Analog
(A) Molecular surface representation of the GMP-CP binding site on the top face of the propeller. The GMP-CP molecule is shown in a ball-
and-stick representation. The solvent-accessible surface is colored according to the local electrostatic potential, ranging from 25 V in dark
blue (most positive) to 80 V in deep red (most negative).
(B) Stereo view of the nucleotide binding pocket. The human apyrase 	 carbon backbone is shown as a gray worm. Residues important for
GMP-CP and Ca2 binding are shown and labeled (carbon, yellow; nitrogen; blue; oxygen, red). The bound GMP-CP molecule (carbon, gray;
nitrogen, blue; oxygen, red; phosphorous, green), the Ca2 ion (green sphere), and selected ordered waters (red spheres) are also shown.
(C) Simulated annealing omit map showing bound GMP-CP in a 2Fo  Fc difference Fourier synthesis, calculated with the ligand removed
from the model and contoured at 1.0.
(D) The 2Fo  Fc electron density map at 1.0 contour in the active site showing “sandwich” ring stacking between the guanine base of GMP-
CP and the side chains of Trp165 and Tyr239.
(E) The 1.6 A˚ 2Fo  Fc electron density map at 1.0	 contour showing the hydrogen bonding network of the phosphate recognition pocket.
Water molecules are shown as red spheres, and hydrogen bonds are denoted by pink dotted lines. Hydrogen bond distances are given in A˚.
(OH-N3  2.9 A˚ and OH–2OH  2.5 A˚) (Figure 3B). Our Glu98, and Asp114 collaborate to position a well-
ordered water molecule that interacts with the 
-phos-structure reveals that nucleotide recognition specificity
is achieved by a combination of stacking interactions phate (Figure 3B). A pentad of alternating positively and
negatively charged residues (Asp46, Lys326, Glu297,and van der Waals contacts, together with satisfaction
of hydrogen bond donors and acceptors from Tyr239 Arg232, and Glu216) creates an intricate network of four
salt bridges in which the Glu297 carboxylate serves asand a set of polar residues flanking the cleft. As evident
from the high degree of sequence conservation, each a bridging arm (Figure 3B). Consequently, Lys326 and
Arg232 make direct side chain contacts with theapyrase family member sandwiches and traps the nucle-
otide base in a similar manner, but with interesting varia- 
-phosphate: Asp46 and Glu297 position Lys326, and
similarly Glu297 and Glu216 fix Arg232. The guanidiniumtions because some key residues in or near the cleft are
not as highly conserved as discussed below. N atom of Arg233 also participates in a water-mediated
hydrogen bond with the 	-phosphate (Figure 3B). AllThe phosphate recognition pocket is lined mostly by
hydrophilic residues, surrounded at the periphery by these phosphate-liganding residues except Arg233 are
absolutely conserved among apyrase proteins, presum-polar and favorable electrostatic interactions (Figure
3B). The observed electron density and predicted hydro- ably reflecting selective pressure on the protein-phos-
phate interactions to maintain active site chemical re-gen bonding are consistent with four water molecules
in the pocket (Figure 3E). The carboxylate group of quirements for catalysis.
The aforementioned calcium ion is located close to theGlu147 is well positioned to receive four water-mediated
hydrogen bonds with the phosphate groups of the li- nucleotide binding site, and was observable as strong
densities in the Fo  Fc map of the substrate analoggand, and a triad of negatively charged residues Asp44,
Cell
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structure. The Ca2 ion is hexahedrally coordinated by tant proteins examined are properly folded in terms of
secondary structure and monomeric state (as judgedthe carbonyl oxygens of Ser100, Glu147, Glu216, Ser277,
and Glu328 (from each blade of the propeller), and a by circular dichroism and sedimentation equilibrium ex-
periments). GDPase activities of the mutant enzymeswater molecule (Figure 3B). Comparison of the structure
of human apyrase in the presence and absence of GMP- were measured in the presence of 2 mM CaCl2, a physio-
logical calcium concentration in the vascular environ-CP reveals that ligand binding induces a shift in the
calcium coordination geometry from heptahedral to hex- ment (Vargas et al., 1998). Substitution of Trp165 and
Tyr239 centered in the hydrophobic cleft by alanine se-ahedral without significant changes in protein conforma-
tion. This geometric change of the Ca2 chelation is verely reduces catalytic efficiency (kcat/Km) (Table 2), indi-
cating the importance of these two conserved aromaticaccomplished by movement of the side chain of Asp101
upon ligand binding: the -carboxylate group is hydro- side chains in engaging the nucleotide base once sub-
strate is bound. The same adverse effect is observedgen-bonded with the main chain NH of Leu149 in the
substrate analog structure while it is coordinated in uni- upon switching two highly conserved residues (Lys163
and Thr166) situated on the right wall of this cleft todentate fashion to the calcium ion in the apo enzyme.
This local conformational change in the conserved alanine (Table 2). Disruption of the electostatic interac-
tions in the salt bridge network (Asp46, Glu216, Arg232,acidic side chain directly adjacent to the Ca2-coordi-
nated residue Ser100 is likely to be important for the Glu297, and Lys326) results in a decrease of enzymatic
activity by a factor of 3–46 fold (Table 2). These dataCa2-dependent catalytic reaction (see below). It is also
notable that Glu147, an invariant residue in the loop implicate Arg232 and Lys326 as key residues in main-
taining salt bridge connections between the five chargedconnecting strands 
2d and 
3a, is involved in contacts
with both the calcium ion and the 
-phosphate (Figure residues as well as concurrent contacts with the nucleo-
tide 
-phosphate. Such contacts may orient and polar-3B). Together these results suggest that the calcium ion
is also a direct component of the active site, consistent ize the 
-phosphate, providing a structural explanation
for the presence of the invariant charged pentad in thewith biochemical evidence that removal of Ca2 com-
pletely abolishes the nucleotidase activity of apyrase catalytic center. Furthermore, mutations of three abso-
lutely conserved negatively charged residues (Asp44,proteins (Smith et al., 2002; Failer et al., 2002).
Asp114, and Glu147) reduce the catalytic rate constant
(kcat) by1000-fold (Table 2), supporting our hypothesisMechanistic Clues
that these amino acids play a role in nucleophilic attackExamination of the substrate analog structure around
on the 
-phosphate group. Finally, the E98Q and K233Athe phosphate recognition pocket suggests no obvious
mutants have GDPase activity 20- and 156-fold lowercandidate for a residue to carry out a nucleophilic attack
than the wild-type enzyme, respectively (Table 2). Thus,on the phosphorus atom of the nucleotide (Figure 3E).
both the hydrogen bonding network and the electro-Indeed, there is presently no evidence for the existence
static field of the active-site environment created byof a phosphoenzyme intermediate formed during the
these charged residues influence nucleotide bindingenzyme’s catalytic cycle. However, there are three water
and hydrolysis.molecules (denoted as w1, w2, and w3) located adjacent
The role of Ca2 in catalysis also has been determinedto the 
-phosphate of the ligand. The distances to the
through site-specific mutagenesis of five coordinating
-phosphate center on the bound nucleotide from the
residues (Ser100, Asp101, Glu216, Ser277, and Glu328).oxygen of w1, w2, and w3 are 3.90, 3.74, and 3.76 A˚,
The E216Q, S277A, and E328Q mutants show a 1.5–15-respectively. This leads us to suggest a promoted-water
fold decrease in kcat/Km (Table 2). On the other hand,mechanism for the apyrase reaction in which the phos-
the S100A and D101N mutations result in at least anpho group is transferred to water. Although none of
additional 10-fold loss of activity (Table 2), which maythese waters is located in an optimal orientation for a
reflect the importance of the observed side chain flip ofpotential in-line attack on the 
-phosphate group, it is
Asp101 in response to the binding of ligand at the activepossible that the GMP-CP substrate analog structure
site. In addition, replacement of Glu147 by glutamine hasmay not perfectly mimic the geometry of the 
-phos-
a profound effect on kcat/Km (Table 2), which is consistentphate group of the natural substrate. The negatively
with its role in both calcium chelation and phosphatecharged carboxylate of Glu147, which provides a car-
binding. Together, these results reinforce the conjecturebonyl oxygen ligand for the calcium ion, is ideally located
that the Ca2 ion plays a role both in promoting catalysisto act as a general base and promote nucleophilic attack
and in the structural stabilization described above (Mur-by the w1 and w2 molecules on the 
-phosphate in the
phy et al., 2003). Based on the apparent proximity of thefirst step of the catalytic reaction, for example (Figure
nucleotide’s 
-phosphate group to the calcium binding3E). Similarly, Asp44, Glu98, and Asp114 provide critical
site, we propose that Asp101 and Glu147 are specificallyhydrogen bonding interactions that may be responsible
involved in coupling calcium binding to substrate bind-for the nucleophilic promotion of the attacking w3 mol-
ing and catalysis in the catalytic pocket of the enzyme.ecule.
Kinetic Properties of Active-Site Mutants Determinants of Substrate Specificity
Our structural and biochemical study suggests that theTo clarify the functional role of individual residues in the
active site, we have used site-directed mutagenesis to striking difference in substrate preference between hu-
man and insect apyrases (GDP versus ADP) results fromalter asparatate and glutamate residues to the corre-
sponding asparagine and glutamine side chains and divergence at one or more of the nonconserved active-
site residues (Figure 2). We asked if it would be possibleother amino acids to alanine. All purified active-site mu-
Protein Design of a Platelet Function Inhibitor
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Table 2. Kinetic Analysis of GDPase Activity of the Active-Site Mutantsa
Normalized values
Human apyrase Km (mM) kcat (min1) kcat/Km (M1 min1) (kcat/Km)
Wild type 1.2 1.2  104 1.0  107 1.0
D44N 0.5 57 1.1  105 0.01
D46N 0.6 5.4  102 9.0  105 0.09
E98Q 1.8 8.8  102 4.9  105 0.05
S100A 3.1 2.5  102 8.1  104 0.008
D101N 0.4 1.7  102 4.3  105 0.04
D114N 1.7 7 4.1  103 0.0004
E147Q 0.3 20 6.7  104 0.007
K163A 0.6 96 1.6  105 0.02
W165A 5.7 4.9  102 8.6  104 0.009
T166A 2.0 1.2  103 6.0  105 0.06
E216Q 1.5 4.9  103 3.3  106 0.3
R232A 0.6 1.3  102 2.2  105 0.02
R233A 1.2 77 6.4  104 0.006
Y239A 0.5 1.0  102 2.0  105 0.02
S277A 0.8 5.5  103 6.9  106 0.7
E297Q 2.1 2.9  103 1.4  106 0.1
K326A 0.9 6.7  102 7.4  105 0.07
E328Q 0.5 3.4  102 6.8  105 0.07
a Average values from three determinations are given (standard errors of approximately  5%).
to engineer a human enzyme capable of efficiently hy- dependence of human apyrase activity could be related
to exposure of the catalytic site of the molecule to thedrolyzing its nonpreferred nucleotide ADP. We therefore
undertook a structure-guided mutational analysis of the organelle lumen in vivo, where the calcium concentra-
tion is much higher than that found intracellularly (Mel-human apyrase protein to identify and incorporate resi-
due(s) that are altered in the insect enzymes and which dolesi and Pozzan, 1998).
The fact that wild-type human apyrase cannot achievecontribute to preference for ADP as substrate. By substi-
tuting 35 insect apyrase residues individually into the the level of hydrolytic activity of the E178M mutant on
addition of exogenous calcium points to a specific rolehuman protein, we determined that the E178M mutation
enhances the hydrolysis rate of both ADP and GDP by of the Glu178→Met substitution in the catalytic reaction.
This supports our hypothesis that an interplay betweena factor 5- to 7-fold (Table 3), whereas all other mutants
are substantially less active than the wild-type enzyme the calcium binding site and the nucleotide binding
pocket is required to create the proper electrostatic(data not shown). Interestingly, kinetic analysis indicates
that the E178M enzyme not only has a greater affinity environment and geometry for catalysis. Glu178 imme-
diately precedes strand 
3c, well away from the calciumfor nucleotide substrate but also is more efficient as a
catalyst (Table 3). Unexpectedly, this rate acceleration binding site and the catalytic center. The carbonyl group
of Glu178 forms a direct hydrogen bond to the NH ofcan be attributed to the reduced calcium requirements
of the E178M mutant for catalysis. Concentrations of Trp194, whereas its side chain is oriented to make polar
contacts with the NH of Glu164 (via two bridging waterCa2 needed to generate 50% of the maximal ADPase
and GDPase activity (Ka) are 1.6 mM and 0.8 mM, respec- molecules). This Glu178-Glu164 interaction thus is likely
to rigidify the 3b-3c loop conformation. The crystaltively, as compared to those of 5.2 mM and 3.1 mM
for the wild-type enzyme. The known higher calcium structure of the E178M apo enzyme at 1.85 A˚ reveals
Table 3. Kinetic Parameters and Substrate Preference for Human Apyrase Variantsa
ADPase/GDPase
Human Apyrase Substrate Km (mM) kcat (min1) kcat/Km (M1 min1) Activity Ratio
Wild type GDP 1.2 1.0  104 1.0  107 0.005
ADP 2.6 1.4  102 5.4  104
E178M GDP 0.5 2.3  104 4.6  107 0.008
ADP 1.4 5.2  102 3.7  105
G160S/L161S/ GDP 0.9 9.2  103 1.0  107 0.02
T168K ADP 2.2 3.6  102 1.6  105
G160S/L161S/ GDP 0.3 1.2  104 4.0  107 0.03
T168K/E178M ADP 1.4 1.4  103 1.0  106
K163A GDP 0.6 96 1.6  105 2.8
ADP 2.7 1.2  103 4.4  105
G160S/L161S/ GDP 0.6 8.6  102 1.4  105 41.4
K163M/T168K/ ADP 0.5 2.9  103 5.8  106
E178M
a Average values from three determinations are given (standard errors of approximately  5%).
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that the carbonyl group of Met178 remains in essentially apyrase for ADP by more than 100-fold. Further studies
the same position for forming a hydrogen bond with are required to determine the precise mechanism by
Trp194 and that there are no perturbations in the coordi- which each of the substitutions described above con-
nation geometry of Ca2 with its ligands (data not tributes to this final enhancement.
shown). The gain of hydrolytic activity in the E178M
mutant might then reflect increased flexibility of the ac- Inhibition of Platelet Function
tive site 3b-3c loop that is no longer constrained by The unique preference of HB-apyrase for the substrate
water-mediated hydrogen bonds. Thus, the gain of ac- ADP strongly suggests that it may have potential to
tivity might not be due to introduction of methionine per block platelet responsiveness to the prothrombotic ago-
se, but simply to the absence of glutamate at that po- nist ADP. To test this hypothesis, cell-based aggreg-
sition. ometry experiments were performed by preincubating
The dramatic effect of the Glu178→Met substitution human platelets with saline (control) and HB-apyrase
on catalysis motivated us to examine the potential role prior to ADP challenge. An overlay of aggregation trac-
of the structurally conserved 3b-3c loop in substrate ings depicting the ability of HB-apyrase to prevent plate-
recognition. Four of the 19 positions (Gly160, Leu161, let aggregate formation is shown in Figure 4A. Addition
Thr168, and Glu178) within this loop are uniquely con- of 10M ADP to saline-treated platelet-rich plasma from
served in each apyrase subfamily (Figure 2). Gly160 and healthy nonmedicated individuals results in a full, irre-
Leu161 are involved in formation of the floor of the ac- versible platelet aggregation response within the first 4
tive-site cleft, and side chain of Leu161 makes van der min, whereas partially reversible aggregation occurs at
Waals contacts with the guanine base of the bound lower ADP concentrations (data not shown). In sharp
nucleotide. Thr168 is solvent exposed and lines the contrast, HB-apyrase abrogates platelet aggregation
opening of the cleft directly adjacent to Tyr239 that is elicited by 10 M ADP in a concentration-dependent
positioned to interact with the guanine base. The individ- manner, resulting in partial and complete inhibition of
ual G160S, L161S, and T168K substitutions impair hu- platelet reactivity at 0.25 M and 0.5 M, respectively.
man apyrase activity as discussed above. However, we In the presence of 0.5 M HB-apyrase, platelet aggrega-
considered that our single residue replacement ap- tion abruptly terminates and the curve rapidly returns
proach might be complicated by the lack of any coordi- to baseline aggregation (Figure 4A). Higher concentra-
nated effect of the three substituted positions. Thus, we tions of HB-apyrase have an even more profound inhibi-
simultaneously introduced the three amino acid changes tory effect, virtually eliminating the initial burst of aggre-
into human apyrase, and indeed, the G160S/L161S/ gation induced by 10M ADP. Wild-type human apyrase
T168K mutant has ADPase activity 3-fold greater than with 107-fold lower ADPase activity relative to HB-apyr-
the wild-type enzyme, while its GDPase activity remains ase fails to inhibit ADP-induced platelet activation even
unchanged (Table 3). The E178M mutation, which itself when a concentration of 10 M was used (Figure 4B).
increases catalytic activity of human apyrase (see The E178M mutant with 16-fold lower ADPase activity
above), combines synergistically with G160S/L161S/ is still capable of suppressing platelet aggregation with
T168K to create a enzyme with a 19- and 4-fold increase
complete inhibition of aggregation around 10M (Figure
in kcat/Km for ADP and GDP, respectively (Table 3). As 4B), although much less effectively than HB-apyrase.
expected, this enzyme exhibits 3.5-fold lower calcium
We conclude that HB-apyrase is an effective inhibitor
dependence for ADP hydrolysis (Table 3).
of platelet reactivity and that its ADPase activity is theAn additional 3b-3c loop mutation (Lys163→Ala) was
sole determinant of platelet function inhibition.found to cause a 63-fold decrease in GDPase activity
To determine the capacity of HB-apyrase to dissipate(Table 2), presumably due to disruption of a direct ionic
freshly created platelet aggregates in vitro, human plate-hydrogen bond between Lys163 and the guanine base
lets were first stimulated with 10 M ADP, then varyingof the bound nucleotide (N–O6  2.8 A˚) (Figure 3B).
amounts of the enzyme were added after initiation ofHowever, the K163A enzyme displays an 8-fold increase
platelet aggregation. Platelet disaggregation was de-in ADPase activity (Table 3). Thus, the side chain of
tected by comparing the extent of light transmittancethe Lys163 position is of decisive importance to human
at 2 min after addition of either HB-apyrase or saline toapyrase in structural discrimination between the sub-
platelet-rich plasma. Addition of HB-apyrase to a sus-strates ADP and GDP, although we cannot infer how
pension of aggregating platelets at 2 min after ADP treat-such discrimination is achieved from our crystal struc-
ment results in a concentration-dependent dispersiontures. Lys163 is conserved in human, rat, and bed bug
of platelet aggregates (Figure 4C). Both the rate andapyrases, but is an isoleucine in the sand fly enzyme
extent of disaggregation are dependent on the concen-(Figure 2). Substitution of a bulky hydrophobic side chain
tration of the enzyme. Concentrations of HB-apyrasefor Lys163 in the G160S/L161S/T168K/E178M enzyme
that normally produce partial (0.25 M) and completewould be predicted to exert an additional synergy on
(0.5 M) inhibition of the initial activation phase of plate-its preference for ADP over GDP as substrate. Gratify-
let aggregation (see above) display limited disaggregat-ingly, the K163M mutation gains a further increase of
ing effects (Figure 4C). However, extensive dispersion6-fold in ADPase activity and a decrease of 71-fold in
of platelet aggregates is achieved at HB-apyraseGDPase activity (Table 3). The engineered G160S/
concentration  1 M. The amount of disaggregationL161S/K163M/T168K/E178M enzyme (denoted HB-
(expressed as a percent of control) produced by HB-apyrase) also demonstrates an ADPase/ATPase activity
apyrase was determined in a concentration range fromratio of 21 (data not shown). As a result of this com-
0.25 M to 5 M, which leads to disaggregation by 16%bined structural biology and design approach, we have
been able to shift the substrate specificity of human to 80%, respectively (Figure 4C). Thus, the concentra-
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Figure 4. Inhibition and Reversal of Human
Platelet Reactivity by HB-Apyrase
(A) Concentration-dependent inhibition of
ADP-induced platelet aggregation by HB-
apyrase. Platelets were preincubated with
HB-apyrase 4 min prior to stimulation with 10
M ADP.
(B) Inhibition of ADP-induced platelet aggre-
gation by the E178M mutant. Wild-type hu-
man apyrase (10 M) has no inhibitory effect
on platelet aggregation.
(C) Dispersal of newly formed platelet aggre-
gates by HB-apyrase. HB-apyrase was added
to platelets 2 min after ADP challenge. The
percent disaggregation was determined by
comparing the extent of aggregation at 2 min
post-HB-apyrase addition to the level of ag-
gregation observed in the presence of saline
(control). The bars represent mean values 
standard deviation from three determina-
tions.
(D) Concentration-dependent attenuation of
collagen-induced platelet aggregation by
HB-apyrase. Wild-type human apyrase (10
M) has no inhibitory effect on platelet aggre-
gation response to 3 g/ml collagen.
tions of HB-apyrase for dissolution of platelet aggre- ase activity. Taken together, the in vitro platelet aggrega-
tion inhibitory properties of HB-apyrase appear ideal forgates are approximately 2- to 3-fold higher than those
for inhibition of platelet aggregation. In addition, when antiplatelet therapy: it both prevents additional platelet
deposition onto existing thrombi and facilitates the dis-assessed after the aggregation curve reaches half-maxi-
mal aggregation (at 30 s after ADP challenge), lower persion of platelets from the occlusive mass.
Both ATP and ADP are released from platelet denseconcentrations of HB-apyrase (0.1 M to 0.3 M) do
not promote disaggregation, but prevent further platelet granules in similar concentrations in response to vascu-
lar injury (Luthje, 1989). CD39 hydrolyzes ATP and ADPactivation and recruitment, as evidenced by the lack of
further increase in light transmittance immediately after with approximately the same activity, a feature that is
presumably relevant for controlling transient high peri-addition of the enzyme (data not shown). The capacity
of HB-apyrase (0.25 M) to disaggregate platelet aggre- cellular ATP and ADP concentrations of the endothelial
cells (Kaczmarek et al., 1996). Recombinant solublegates increases from 16 to 45% as the delay between
the time of ADP and HB-apyrase addition decreases CD39 has been shown to release ADP as an intermediate
during ATP hydrolysis (Chen and Guidotti, 2001), andfrom 2 min to 30 s. We conclude that HB-apyrase facili-
tates the dispersal of aggregated platelets during the this ATP to ADP conversion by soluble CD39 has been
found to result in low but detectable levels of plateletinitial recruitment phase in vitro.
aggregation (Sevigny et al., 2002). Thus, ATPase andSince platelet aggregation in response to collagen
ADPase activities of CD39 have opposing actions ontreatment can lead to secretion of granule contents with
platelet aggregation in vitro, which may potentially com-subsequent activation of platelets by released endoge-
plicate therapeutic regimens with CD39-based pharma-nous ADP (Clemetson and Clemetson, 2001), we ex-
cological agents. In contrast, HB-apyrase described inpected that HB-apyrase would be effective in attenuat-
this paper is a selective inhibitor of ADP-induced plateleting the agonistic effects of collagen. Indeed, platelet
aggregation. Given its independent mode of action andaggregate formation when platelets are challenged by
ease of production, HB-apyrase alone or in combination3g/ml collagen is inhibited by HB-apyrase in a concen-
with heparin, aspirin, and GPIIb/IIIa antagonists couldtration-dependent fashion (Figure 4D). HB-apyrase at
become a therapeutic option for patients with acuteconcentrations of 1 M, 2.5 M, and 10 M reduces the
coronary syndromes.extent of platelet aggregation by 27%, 31%, and 43%,
respectively, as compared to saline-treated plasma. In
Experimental Procedurescontrast, wild-type human apyrase at 10 M has no
inhibitory effect on platelet responsiveness to collagen Protein Expression and Purification
(Figure 4D). Thus, the ability of HB-apyrase to decrease The mature human apyrase protein (residues 3–333) was expressed
in E. coli BL21 (DE3)/pLysS using a modified pET3a vector. Thecollagen-mediated platelet reactivity is due to its ADP-
Cell
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cells from a 2 liter culture were harvested by centrifugation 4 hr as previously described (Fiske and Subbarow, 1925; Smith et al.,
2002). When greater sensitivity was required, the method of Baykovpostinduction with 0.5 mM IPTG, and the pellets were resuspended
in 50 ml of buffer A (50 mM Tris-HCl [pH 8.0], 1 mM EDTA) plus et al. (1988) was used. Conditions were chosen such that 10% of
the added nucleotides were hydrolyzed during the course of the25% sucrose. The cells were lysed by sonication and centrifuged
to separate the soluble fraction from inclusion bodies. The inclusion experiments, thus allowing data fitting to hyperbolic curves and the
Michaelis-Menten equation for determination of Km and kcat. Thebodies were subsequently washed extensively with buffer A plus
1% Triton X-100. Recombinant human apyrase was purified directly calcium activation constants (Ka) were determined in 50 mM Tris-
HCl [pH 6.9] and 100 mM NaCl containing 2 mM substrate nucleotidefrom the inclusion bodies resuspended in 3 M urea/buffer A. The
debris was removed by a 1 hr centrifugation at 4C. The enzyme and 0.1–10 mM CaCl2.
was refolded by step dialysis in buffer A with decreasing amounts
of urea at 4C. Refolded human apyrase was then loaded onto a Platelet Aggregation
DEAE Sepharose column equilibrated with buffer A and eluted using Blood was collected in sodium heparin anticoagulant (final concen-
a NaCl gradient in buffer A. The sample was dialyzed into buffer A, tration 14 U/ml) from healthy, nonmedicated donors. Platelet-rich
concentrated 25 by ultrafiltration, and applied to a MonoQ col- plasma (PRP) was prepared by centrifugation at 450 g for 10 min
umn equilibrated with buffer A. The enzyme was eluted from the at room temperature. PRP was carefully removed and the remaining
MonoQ resin with a NaCl gradient in buffer A. The sample was blood sample was centrifuged at 2000 g for 10 min at room tempera-
concentrated, loaded onto a Superdex 200 size exclusion column, ture to isolate platelet-poor plasma (PPP). Platelets were adjusted to
and equilibrated with buffer B (50 mM Tris-HCl [pH 8.0], 150 mM 2  105 platelets/l using PPP. Platelet aggregation was monitored
NaCl). Recombinant human apyrase eluted as a single species. Frac- using a four-channel aggregometer. PRP (230 l) was incubated at
tions containing the enzyme were pooled and concentrated by ultra- 37C for 3 min with various concentrations of either 10 l of HB-
filtration to about 15 mg/ml and stored at 4C. Selenomethionine- apyrase or saline. Baseline aggregation was then monitored for 1
substituted human apyrase was produced for MAD analysis in amino min prior to addition of agonist. After the incubation period, 10 l
acid-supplemented minimal media and purified as described above. of agonist (ADP, collagen) was added to the cuvette and changes
in light transmission were monitored for 4 min. For each platelet
Crystallization and Structure Determination disaggregation assay, ADP (10 l) was added to PRP (230 l) and
Crystals were obtained by hanging-drop vapor diffusion in 5 days the cuvette was incubated at 37C. At 30 s and 2 min after addition
at room temperature by equilibrating against buffer C (10%–15% of ADP, 10 l of HB-apyrase or saline was added to the sample
PEG MME 2000, 100 mM NaOAc [pH 5.0], 0.3–0.4 M (NH4)2SO4), a and disaggregation was monitored for 2 min after addition of HB-
solution containing 0.9 l of protein sample (15 mg/ml) in the pres- apyrase. Results were expressed as the percent decrease in platelet
ence and absence of 20 mM nucleotide ligand, 0.2 l of SrCl2 (100 aggregation at 2 min after addition of HB-apyrase, compared to the
mM), and 0.9 l of buffer C. Crystals belong to space group P1 (a  level of aggregation observed at the same time in the presence of
43.20 A˚, b  52.5 A˚, c  77.9 A˚, 	  99.4, 
  106.6,   99.9) saline. Data are expressed as follows: % disaggregation  100 
with two molecules in the asymmetric unit. The crystals were trans- [(% light changes of the saline-treated PRP) – (% light changes of
ferred to 15% glycerol in buffer C and frozen in liquid nitrogen HB-apyrase-treated PRP)]/(% light changes of the saline-treated
for data collection. Data sets Native, SeMet, and GMP-CP were PRP).
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